Pharmasyntez is currently implementing four investment projects in the Irkutsk region, two of which have already reached the launch stage. Two more have so far only received support from the regional governor and the mayor of the regional capital, Irkutsk. The president of the Pharmasyntez group of companies, Vikram Punia CEO, stated during a working meeting with the head of the Irkutsk region, Igor Kobzev, that the implementation of four projects will require a total of 5 billion rubles.
In the near future, bronchodilator drugs for the treatment of bronchial asthma and chronic obstructive pulmonary disease will be produced at the Irkutsk site. There, by the end of the year, a new production of sterile dosage forms in ampules and syringes will be launched. We are talking about drugs that are used for the prevention and treatment of common and socially significant diseases.
Furthermore, a pharmaceutical substance production facility is set to open in Bratka. “We are launching 4 new units, and 10 new lines in the city of Bratsk for the production of pharmaceutical substances. This is very important, because if we do not produce our own pharmaceutical substances, then we cannot talk about medicinal sovereignty,” Punia said. He did not specify which substances he was talking about.
Two future investment projects involve the construction of a packaging materials plant and a new production of pharmaceutical drugs in Irkutsk. “In total, we are currently investing more than 3 billion rubles in the development of the Irkutsk region within the framework of already implemented socially significant projects, and <…> in the next two years we will additionally invest at least 2 billion rubles in the creation of import-substituting industries,” – Punia said, adding that together all four projects will create more than 300 jobs in the region.
Governor Igor Kobzev highly praised the activities of the Pharmasyntez company, calling it “a powerful impetus for the development of the pharmaceutical industry in the Irkutsk region.” According to him, the company occupies a key position in the production of import-substituting products.
